Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein

Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318 · see citing works

DNA Vaccines: Immunology, Application, and Optimization

Gurunathan, S., Klinman, D. M., & Seder, R. A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.927 · Cited by 1,198 · see citing works

DNA VACCINES

Donnelly, J., Ulmer, J. B., Shiver, J. W., & Liu, M. A. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.617 · Cited by 985 · see citing works

Nonviral delivery of self-amplifying RNA vaccines

Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 6× · see citing works

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501 · see citing works

A structural and functional perspective of alphavirus replication and assembly

Jose, J., Snyder, J. E., & Kuhn, R. J. (2009) · Future Microbiology · doi:10.2217/fmb.09.59 · Cited by 413 · see citing works

A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines

Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338 · see citing works

The history of MF59 ® adjuvant: a phoenix that arose from the ashes

O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 318 · see citing works

Recognition of viral nucleic acids in innate immunity

Yoneyama, M., & Fujita, T. (2009) · Reviews in Medical Virology · doi:10.1002/rmv.633 · Cited by 303 · see citing works

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · cited 2× · see citing works

Mechanism of action of mRNA-based vaccines

Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · see citing works

Rapidly produced SAM ^® vaccine against H7N9 influenza is immunogenic in mice

Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., et al. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.54 · Cited by 226 · see citing works

Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis

Schmaljohn, A. L., Johnson, E. D., Dalrymple, J. M., & Cole, G. A. (1982) · Nature · doi:10.1038/297070a0 · Cited by 220 · see citing works

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R. A., Hoeper, A., Morris, J., Negri, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.135 · Cited by 212 · see citing works

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

Pittman, P. R., Makuch, R. S., Mangiafico, J. A., Cannon, T. L., Gibbs, P., & Peters, C. J. (1996) · Vaccine · doi:10.1016/0264-410x(95)00168-z · Cited by 212 · see citing works

Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design

Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208 · see citing works

Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey

Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195 · see citing works

RNA-based vaccines

Ulmer, J. B., Mason, P. W., Geall, A. J., & Mandl, C. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.060 · Cited by 183 · see citing works

Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion

Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181 · see citing works

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154 · see citing works

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens

Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., & Maione, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.040 · Cited by 149 · see citing works

Biological Weapons—a Primer for Microbiologists

Hawley, R. J., & Eitzen, E. M. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.235 · Cited by 146 · see citing works

New PARP Gene with an Anti-Alphavirus Function

Atasheva, S., Akhrymuk, M., Frolova, E. I., & Frolov, I. V. (2012) · Journal of Virology · doi:10.1128/jvi.00733-12 · Cited by 139 · see citing works

Self-replicating alphavirus RNA vaccines

Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 137 · see citing works

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus

Mellquist-Riemenschneider, J. L., Garrison, A. R., Geisbert, J. B., Jahrling, P. B., Hevey, M., Negley, D. L., Schmaljohn, A. L., Lee, J., Hart, M. K., Vanderzanden, L., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00362-1 · Cited by 133 · see citing works

DNA vaccines for viral infections: Basic studies and applications

Robinson, H. L., & Pertmer, T. M. (2000) · Advances in virus research · doi:10.1016/s0065-3527(00)55001-5 · Cited by 126 · see citing works

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

Mandl, C. W., Aberle, J. H., Aberle, S. W., Holzmann, H., Allison, S. L., & Heinz, F. X. (1998) · Nature Medicine · doi:10.1038/4031 · Cited by 124 · see citing works

Vaccines for Venezuelan equine encephalitis

Paessler, S., & Weaver, S. C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.095 · Cited by 114 · see citing works

The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes

Roehrig, J. T., & Mathews, J. H. (1985) · Virology · doi:10.1016/0042-6822(85)90343-5 · Cited by 110 · see citing works

Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies.

Mathews, J. H., & Roehrig, J. T. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.6.2763 · Cited by 106 · see citing works

Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection

Baeza Garcia, A., Siu, E., Sun, T., Exler, V., Brito, L., Hekele, A., Otten, G., Augustijn, K., Janse, C. J., Ulmer, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05041-7 · Cited by 97 · see citing works

A DNA Vaccine for Venezuelan Equine Encephalitis Virus Delivered by Intramuscular Electroporation Elicits High Levels of Neutralizing Antibodies in Multiple Animal Models and Provides Protective Immunity to Mice and Nonhuman Primates

Dupuy, L. C., Richards, M. J., Ellefsen, B., Chau, L., Luxembourg, A. T., Hannaman, D., Livingston, B. D., & Schmaljohn, C. S. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00030-11 · Cited by 82 · see citing works

Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus

Reed, D. S., Lind, C. M., Lackemeyer, M. G., Sullivan, L. J., Pratt, W. D., & Parker, M. D. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.12.023 · Cited by 80 · see citing works

Rational design of gene‐based vaccines

Barouch, D. H. (2005) · The Journal of Pathology · doi:10.1002/path.1874 · Cited by 73 · see citing works

A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation

Hannaman, D., Dupuy, L. C., Ellefsen, B., & Schmaljohn, C. S. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.077 · Cited by 70 · see citing works

Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice

Ludwig, G. V., Turell, M. J., Vogel, P., Kondig, J. P., Kell, W. K., Smith, J. F., & Pratt, W. D. (2001) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.2001.64.49 · Cited by 67 · see citing works

Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection

Paessler, S., Yun, N., Judy, B., Dziuba, N., Zacks, M., Grund, A. H., Frolov, I., Campbell, G., Weaver, S., & Estes, D. M. (2007) · Virology · doi:10.1016/j.virol.2007.05.041 · Cited by 66 · see citing works

Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies

Mathews, J. H., Roehrig, J. T., & Trent, D. W. (1985) · Journal of Virology · doi:10.1128/jvi.55.3.594-600.1985 · Cited by 64 · see citing works

Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice

Hart, M. K., Pratt, W. D., Panelo, F., Tammariello, R. F., & Dertzbaugh, M. T. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00204-6 · Cited by 61 · see citing works

Novel Vaccine against Venezuelan Equine Encephalitis Combines Advantages of DNA Immunization and a Live Attenuated Vaccine

Tretyakova, I., Lukashevich, I., Glass, P., Wang, E., Weaver, S., & Pushko, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.050 · Cited by 58 · see citing works

Combined Alphavirus Replicon Particle Vaccine Induces Durable and Cross-Protective Immune Responses against Equine Encephalitis Viruses

Reed, D. S., Glass, P. J., Bakken, R. R., Barth, J. F., Lind, C. M., da Silva, L., Hart, M. K., Rayner, J. O., Alterson, K., Custer, M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01406-14 · Cited by 58 · see citing works

Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates

PRATT, W. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00192-8 · Cited by 56 · see citing works

A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus

Hunt, A. R., Frederickson, S., Hinkel, C., Bowdish, K. S., & Roehrig, J. T. (2006) · Journal of General Virology · doi:10.1099/vir.0.81925-0 · Cited by 55 · see citing works

CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus

Yun, N., Peng, B.-H., Bertke, A., Borisevich, V., Smith, J. K., Smith, J., Poussard, A., Salazar, M., Judy, B., Zacks, M. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.015 · Cited by 47 · see citing works

Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus

PHILLPOTTS, R. J., O’Brien, L. M., Appleton, R. E., Carr, S., & Bennett, A. M. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.06.056 · Cited by 47 · see citing works

T Cells Facilitate Recovery from Venezuelan Equine Encephalitis Virus-Induced Encephalomyelitis in the Absence of Antibody

Brooke, C. B., Deming, D., Whitmore, A. C., White, L., & Johnston, R. E. (2010) · Journal of Virology · doi:10.1128/jvi.02545-09 · Cited by 47 · see citing works

Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus

PHILLPOTTS, R. J., Jones, L. D., & Howard, S. C. (2002) · Vaccine · doi:10.1016/s0264-410x(01)00505-9 · Cited by 45 · see citing works

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies

Loomis, R. J., Lilja, A. E., Monroe, J. E., Balabanis, K. A., Brito, L. A., Palladino, G., Franti, M., Mandl, C. W., Barnett, S. W., & Mason, P. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.009 · Cited by 43 · see citing works

An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine

Bennett, A. M., Elvin, S. J., Wright, A. J., Jones, S. M., & PHILLPOTTS, R. J. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00123-7 · Cited by 40 · see citing works

Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.

Fine, D., Roberts, B., Terpening, S. J., Mott, J., Vasconcelos, D. Y., & House, R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.044 · Cited by 38 · see citing works

Antibody to the E3 Glycoprotein Protects Mice against Lethal Venezuelan Equine Encephalitis Virus Infection

Parker, M. D., Buckley, M. J., Melanson, V. R., Glass, P. J., Norwood, D., & Hart, M. K. (2010) · Journal of Virology · doi:10.1128/jvi.01345-10 · Cited by 37 · see citing works

Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors1In conducting the research described in this report, the investigators adhered to the Guide for Care and Use of Laboratory Animals, as promulgated by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care. The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.1

Hodgson, L. A., Ludwig, G. V., & Smith, J. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00335-1 · Cited by 33 · see citing works

Pseudoinfectious Venezuelan Equine Encephalitis Virus: a New Means of Alphavirus Attenuation

Atasheva, S., Kim, D., Akhrymuk, M., Morgan, D., Frolova, E., & Frolov, I. (2012) · Journal of Virology · doi:10.1128/jvi.02881-12 · Cited by 30 · see citing works

Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection

Brooke, C. B., Schäfer, A., Matsushima, G. K., White, L., & Johnston, R. E. (2011) · Journal of General Virology · doi:10.1099/vir.0.038281-0 · Cited by 26 · see citing works

Role for mucosal immune responses and cell‐mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus*

Elvin, S. J., Bennett, A. M., & PHILLPOTTS, R. J. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10086 · Cited by 24 · see citing works

Toward a crystal-clear view of the viral RNA sensing and response by RIG-I-like receptors

Luo, D. (2014) · RNA Biology · doi:10.4161/rna.27717 · Cited by 24 · see citing works

Cytotoxic T-cell activity is not detectable in Venezuelan equine encephalitis virus-infected mice

Jones, L. D., Bennett, A. M., Moss, S. R., Gould, E. A., & PHILLPOTTS, R. J. (2003) · Virus Research · doi:10.1016/s0168-1702(02)00275-7 · Cited by 19 · see citing works

Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses

Hunt, A. R., & Roehrig, J. T. (1995) · Vaccine · doi:10.1016/0264-410x(95)93315-z · Cited by 18 · see citing works

Improved Efficacy of a Gene Optimised Adenovirus-based Vaccine for Venezuelan Equine Encephalitis Virus

Williams, A., O'Brien, L., Phillpotts, R., & Perkins, S. D. (2009) · Virology Journal · doi:10.1186/1743-422x-6-118 · Cited by 16 · see citing works

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 428 · see citing works

mRNA vaccine: a potential therapeutic strategy

Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422 · see citing works

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368 · see citing works

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261 · see citing works

Formulation and Delivery Technologies for mRNA Vaccines

Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 221 · see citing works

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works

Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm

Wang, W., Feng, S., Ye, Z., Gao, H., Lin, J., & Ouyang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.021 · Cited by 170 · see citing works

mRNA cancer vaccines: Advances, trends and challenges

He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 167 · see citing works

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 146 · see citing works

mRNA vaccines for COVID-19 and diverse diseases

Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 117 · see citing works

Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks

Tayeb, H. H., Felimban, R. I., Almaghrabi, S. A., & Hasaballah, N. H. (2021) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2021.100533 · Cited by 108 · see citing works

DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine

Zhang, R., Tang, L., Tian, Y., Xiao, J., Hu, Q., Zhou, B., Ding, Z., Xu, H., & Yang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.023 · Cited by 101 · see citing works

Messenger RNA-Based Vaccines Against Infectious Diseases

Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96 · see citing works

Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape

Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 96 · see citing works

A new generation of vaccines based on alphavirus self-amplifying RNA

Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador, G., Vanrell, L., & Smerdou, C. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.08.003 · Cited by 87 · see citing works

RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?

Sandbrink, J. B., & Shattock, R. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608460 · Cited by 79 · see citing works

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78 · see citing works

Self-Amplifying RNA Approach for Protein Replacement Therapy

Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76 · see citing works

The Delivery of mRNA Vaccines for Therapeutics

Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 70 · see citing works

Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses

Stromberg, Z., Fischer, W., Bradfute, S. B., Kubicek-Sutherland, J. Z., & Hraber, P. (2020) · Vaccines · doi:10.3390/vaccines8020273 · Cited by 40 · see citing works

Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action

Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 45 · see citing works

Engineered mRNA Delivery Systems for Biomedical Applications

Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 44 · see citing works

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40 · see citing works

Nanocarrier vaccine therapeutics for global infectious and chronic diseases

Simnani, F. Z., Singh, D., Patel, P., Choudhury, A., Sinha, A., Nandi, A., Samal, S. K., Verma, S. K., & Panda, P. K. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.008 · Cited by 37 · see citing works

Data-balanced transformer for accelerated ionizable lipid nanoparticles screening in mRNA delivery

Wu, K., Yang, X., Wang, Z., Li, N., Zhang, J., & Liu, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae186 · Cited by 36 · see citing works

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

Liu, Y., Li, Y., & Hu, Q. (2023) · Vaccines · doi:10.3390/vaccines11071142 · Cited by 27 · see citing works

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases

Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 27 · see citing works

Alphaviruses: Host pathogenesis, immune response, and vaccine & treatment updates

Guerrero‐Arguero, I., Freitas, C. M. T., Weber, K. S., Berges, B. K., Robison, R. A., & Pickett, B. E. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001644 · Cited by 22 · see citing works

The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA

Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 21 · see citing works

Animal vaccine revolution: Nanoparticle adjuvants open the future of vaccinology

Xu, S., Sun, C., Qian, T., Chen, Y., Dong, X., Wang, A., Zhang, Q., Ji, Y., Jin, Z., Liu, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113827 · Cited by 18 · see citing works

Polyplex nanomicelle delivery of self-amplifying RNA vaccine

Chang, Y., Lin, M., Chien, M.-C., Ke, G., Wu, I.-E., Lin, R.-L., Lin, C., & Hu, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.008 · Cited by 18 · see citing works

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy

Hu, C., Liu, J., Cheng, F., Bai, Y., Mao, Q., Xu, M., & Liang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261243 · Cited by 14 · see citing works

Advanced nanoscale delivery systems for mRNA-based vaccines

Mobasher, M., Ansari, R. A., Castejon, A. M., Barar, J., & Omidi, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130558 · Cited by 13 · see citing works

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh, H. A., Pallathadka, H., Hjazi, A. M., Al‐Dhalimy, A. M. B., Zearah, S. A., Ghildiyal, P., Al‐Mashhadani, Z. I., Mustafa, Y. F., Hizam, M. M., & Elawady, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3954 · Cited by 13 · see citing works

Research progress of mosquito-borne virus mRNA vaccines

Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11 · see citing works

A roadmap for developing Venezuelan equine encephalitis virus (VEEV) vaccines: Lessons from the past, strategies for the future

Han, L., Song, S., Feng, H., Ma, J., Wei, W., & Si, F. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125514 · Cited by 9 · see citing works

Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem

Masoumi, F., Saraiva, S. M., Bouzo, B. L., López‐López, R., Esteller, M., Díaz‐Lagares, Á., & de la Fuente, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091507 · Cited by 9 · see citing works

A duplex droplet digital PCR assay for absolute quantification and characterization of long self-amplifying RNA

Casmil, I. C., Huang, C., & Blakney, A. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-46314-6 · Cited by 9 · see citing works

Applications of self-replicating RNA

Lundstrom, K. H. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.006 · Cited by 7 · see citing works

Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism

Lu, H.-H., Alves, R. P. D. S., Li, Q. H., Eder, L., Timis, J., Madany, H., Chuensirikulchai, K., Varghese, K., Singh, A. D., Tran, L. L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187405 · Cited by 6 · see citing works

Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy

Kögel, D., Temme, A., & Aigner, A. M. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108762 · Cited by 7 · see citing works

Transfection via RNA-Based Nanoparticles: Comparing Encapsulation vs Adsorption Approaches of RNA Incorporation

Laturski, A. E., Dulay, M. T., Perry, J. L., & DeSimone, J. M. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00028 · Cited by 6 · see citing works

Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA

Ulmer, J. B., & Liu, M. A. (2021) · Molecular Frontiers Journal · doi:10.1142/s2529732521400022 · Cited by 6 · see citing works

Self-amplifying RNA virus vectors for drug delivery

Lundstrom, K. H. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2445675 · Cited by 5 · see citing works

Can self-amplifying RNA vaccines and viruses exchange genetic material?

Casmil, I. C., & Blakney, A. K. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.003 · Cited by 5 · see citing works

Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?

Tournier, J., & Kononchik, J. P. (2021) · Viruses · doi:10.3390/v13040569 · Cited by 4 · see citing works

Safety and efficacy of RNA vaccines: State of the art

Blagov, A. V., Bukaeva, A. A., Makarov, V. V., & Bochkaeva, Z. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-sae-2320 · Cited by 4 · see citing works

Current status on encephalitic alphavirus vaccines development: Advances, challenges, and global health perspectives

Yang, X., Ning, Y., Xu, C., Zhang, Q., Dong, Y., Wang, Y., 张芳琳, Lei, Y., & Ye, W. (2026) · Infectious Medicine · doi:10.1016/j.imj.2026.100249 · Cited by 2 · see citing works

Application of self-amplifying mRNA technology in the development of infectious disease vaccines

Li, X., Wang, X., & Zhang, B. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0902 · Cited by 2 · see citing works

Strategies of Vaccine Development

Sachdeva, M., & Arora, S. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-4345-3_25 · Cited by 2 · see citing works

RNA vaccines in infectious diseases: A systematic review

Beirigo, E. D. F., Franco, P. I. R., Neto, J. R. D. C., Guerra, R. O., Farnesi-de-Assunção, T. S., Sousa, I. D. O. F., Obata, M. M. S., Rodrigues, W. F., Machado, J. R., & da Silva, M. V. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106372 · Cited by 3 · see citing works

pDNA and mRNA vaccines

Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1 · see citing works

Self‐Replicating RNA Viruses for Vaccine Development

Lundstrom, K. H. (2024) · doi:10.1002/9783527838394.ch4 · Cited by 1 · see citing works

mRNA vaccines: the next frontier in disease prevention

Babar, Q. A., Maryam, M., MUHAMMAD, A. M., Tahir, M. F., & Ali, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00016-9

Why the Jenner/Pasteur paradigm is insufficient for controlling vector-borne diseases and the role of microbiota-mediated interactions

Cano‐Argüelles, A. L., Abuin‐Denis, L., Obregón, D., Mateos‐Hernández, L., Maître, A., Piloto‐Sardiñas, E., Chuang, A. W., Tonnerre, P., & Cabezas‐Cruz, A. (2025) · Current Research in Parasitology and Vector-Borne Diseases · doi:10.1016/j.crpvbd.2025.100291

Venezuelan Equine Encephalitis Virus: Structural Biology, Vaccines, and Advances in Functional Antibodies

Tang, R., Wang, D., Chen, G., Liu, C., Zhang, L., Peng, F., Yu, J., Li, X., Luo, H., Wen, Y., et al. (2025) · Vaccines · doi:10.3390/vaccines14010023

In Trans RNA Replication of a Defective Self-amplifying RNA Lowers RNA Replication But Enhances Protein Translation

Moreno-Gutiérrez, D. S., Duran-Meza, A. L., & Gelbart, W. M. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169988

A Zika virus vaccine with E protein fusion loop mutations protects via CD8+ T cells

Chuensirikulchai, K., Li, Q. H., Lu, H.-H., Timis, J., Montano, M., Eder, L., Bhandari, P., Zyla, D. S., Bunz, M., Madany, H., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02465-6

Computational Design of a Trivalent Multi-Epitope mRNA Vaccine Candidate Against Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Qin, R., Luo, Y., Zhou, Z., Xu, Y., Wu, X., 侯燕群, Chen, J., Zhu, F., & Pan, P. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04192-3

IL7R mRNA therapy enhances antitumor T cell immunity and suppresses tumor growth in preclinical tumor models

Rehman, A. U., Khan, M. A.-U.-R., Akhtar, A., Qin, Q., Zhang, X. X., Asghar, M. A., Ling, D., Wang, P., Luo, Y., Wang, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-017160

Venezuelan equine encephalitis virus: novel live-attenuated vaccines for inducing complete protective immunity

Elliott, K. C., Saunders, D., & Mattapallil, J. J. (2026) · npj Viruses · doi:10.1038/s44298-026-00186-5 · Cited by 2 · see citing works

Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose

Rossi, S., Russell-Lodrigue, K., Plante, K., Bergren, N. A., Gorchakov, R., Roy, C., & Weaver, S. (2020) · Vaccines · doi:10.3390/vaccines8030497 · Cited by 8 · see citing works

Self-amplifying RNA vaccine development: transcriptomic profiling of a Venezuelan equine encephalitis virus self-amplifying RNA vector in human muscle

Barton, R. D. (2022) · doi:10.25560/108206

Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate

Hart, M. K., Caswell-Stephan, K., Bakken, R. R., Tammariello, R. F., Pratt, W. D., Davis, N., Johnston, R. E., Smith, J. M., & Steele, K. E. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00042-6 · Cited by 79 · see citing works

Improved Protection against Venezuelan Equine Encephalitis by Genetic Engineering of a Recombinant Vaccinia Virus

Bennett, A. M., LESCOTT, T., & PHILLPOTTS, R. J. (1998) · Viral Immunology · doi:10.1089/vim.1998.11.109 · Cited by 18 · see citing works